What is the CVR number of SYNACT PHARMA ApS?

SYNACT PHARMA ApS is registered with CVR / Virk under CVR 34459975.

What is the revenue of SYNACT PHARMA ApS?

SYNACT PHARMA ApS reported revenue of DKK -53,2M in 2025.

SYNACT PHARMA ApS employs 7 people as of the latest annual report.

Jeppe Øvli Øvlesen is the CEO of SYNACT PHARMA ApS, in role since 2024.

SYNACT PHARMA ApS's registered address is Dronninggårds Alle 136.

APSActiveAdvertising protection

CVR 34459975Dronninggårds Alle 136, 2840 HolteManufacture of pharmaceutical preparations· NACE 2120Est. 2012 · 14 years old7 employees

Actively employed in the business

Name	Role	Member since
Current (3)
TB Thomas Boesen Management	Management	2023
JØ Jeppe Øvli Øvlesen Chief Executive Officer	Chief Executive Officer	2024
AK Ann Kristin Brøgger Led Management	Management	2026
Former (6)
BU Björn Uno Bernhard Westberg Management	Management	2023 – 2026
HS Henrik Stage Management	Management	2016 – 2022
PR Patrik Renblad Management	Management	2022 – 2023
TB Torbjørn Bjerke Chief Executive Officer	Chief Executive Officer	2023 – 2024
BS Bruno Sten Rosenkrans Jensen Audit	Audit	2012 – 2012
SG Sigbjørn Georg Nielsen Kjærgård Chief Executive Officer	Chief Executive Officer	2012 – 2015

Non-executive oversight

Name	Role	Member since
Former (4)
OB Otto Bjerg Hausgaard Chairman	Chairman	2015 – 2016
UA Uli Alf Hacksell Chairman	Chairman	2013 – 2015
JF Jørn Frederik Falch Board of Directors	Board of Directors	2013 – 2015
TE Thomas Engelbrecht Nordkild Jonassen Board of Directors	Board of Directors	2015 – 2016

As of last annual report

Shareholder	Type	Ownership	Votes	Since
SynAct Pharma AB	Individual	100%	100%	2016
GL Capital AB	Individual	10–14.99%	10–14.99%	2016
Next Stage Ventures ApS	Company	5–9.99%	5–9.99%	2016
TJ BIOTECH HOLDING ApS	Company	33.33–49.99%	33.33–49.99%	2016
Forsknings-, Uddannelses- og Digitaliseringsministeriet	Company	25–33.32%	25–33.32%	2012
QUANTASS ApS	Company	25–33.32%	25–33.32%	2016

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.